Cellebrite Introduces Streamlined Collection & Review to Investigative Analytics Workflow

Rhea-AI Summary

Cellebrite has launched an automated system that integrates investigative analytics, enabling stakeholders to collect, review, and analyze data efficiently. This innovation aims to resolve cases quicker and enhance the workflow for examiners, analysts, and prosecutors by securely storing and decoding evidence. The company's Executive Vice President stated that this system can save hours in the data transfer process, ultimately accelerating justice. Cellebrite, traded on NASDAQ under the symbol CLBT, is committed to enhancing digital investigations.

Positive

• Launch of an automated system to streamline investigative analytics.
• Improved efficiency in case resolution, potentially saving hours in workflows.
• Enhanced scalability, accountability, and auditability in data handling.

Negative

• None.

Integrating the Collection & Review and Investigative Analytics functions resolves cases faster and accelerates time to justice

PETAH TIKVA, Israel and TYSONS CORNER, Va., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (NASDAQ: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced the launch of an automated and secure system that enables investigative analytics stakeholders to collect, review, and analyze data in an integrated workflow.

By providing a secure and frictionless process, Cellebrite is breaking down silos and accelerating the analysis of evidence. The streamlined process gives enriched data to examiners, analysts, and prosecutors to execute their respective roles.

With a more efficient workflow, Cellebrite is eliminating pain points by empowering agencies to provide data to the analysis team rapidly with secure storage and decoding, delivering a richer investigative data set.

Cellebrite is improving scalability, accountability, and auditability compared to previous methods.

Ori Nurick, Executive Vice President of Portfolio Strategy at Cellebrite, stated: “Every second counts in complex examinations that require access to data, and the conversion of retrieved data into a readable format eases the process on law enforcement. By streamlining the transfer of data to the investigative team, we are providing our customers the tools to shave hours off their workflows and bring evidence to prosecutors faster.”

About Cellebrite

Cellebrite’s (NASDAQ: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.

Cellebrite Media
Victor Cooper
Public Relations and Corporate Communications Director
+1 404.804.5910
victor.cooper@cellebrite.com

FAQ

What is the significance of Cellebrite's new automated system launched on August 22, 2022?

Cellebrite's new system integrates investigative analytics, improving data collection, review, and analysis, thus accelerating case resolution.

How does Cellebrite's new system affect law enforcement operations?

The system provides law enforcement with efficient data transfer tools, significantly reducing the time needed to prepare evidence for prosecution.

What is Cellebrite's stock symbol and where is it traded?

Cellebrite is traded on NASDAQ under the stock symbol CLBT.

What benefits does Cellebrite claim its new system provides?

Cellebrite claims the system enhances efficiency, scalability, accountability, and speeds up the delivery of evidence to prosecutors.